Overview

This trial is active, not recruiting.

Condition head and neck cancer
Treatments 5-fu, carboplatin, cisplatin, mehd7945a, paclitaxel
Phase phase 1
Targets EGFR, HER3
Sponsor Genentech, Inc.
Start date September 2013
End date April 2018
Trial size 24 participants
Trial identifier NCT01911598, 2013-001285-42, GO28909

Summary

This open-label, multicenter study will evaluate the safety, tolerability, and pharmacokinetics of MEHD7945A in combination with chemotherapy (either cisplatin plus 5-FU or carboplatin plus paclitaxel) in participants with previously untreated R/M SCCHN. There are two stages for each arm in this study: a Dose-limiting Toxicity (DLT)-evaluation stage (Stage I) and a cohort-expansion stage (Stage II). In Stage I, DLTs will be assessed during a DLT Assessment Window of 21 days (i.e., Cycle 1 Day 1 through Cycle 1 Day 21) for both arms. In Stage II, participants will be enrolled to further characterize the safety, pharmacokinetics, and anti-tumor activity of MEHD7945A in combination with cisplatin + 5-FU or carboplatin + paclitaxel at the identified recommended Phase II dose.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model parallel assignment
Primary purpose treatment
Masking no masking
Arm
(Experimental)
Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
5-fu
5-FU will be administered as per schedule specified in the respective arm.
cisplatin
Cisplatin will be administered as per schedule specified in the respective arm.
mehd7945a Duligotuzumab
MEHD7945A will be administered as per schedule specified in the respective arms.
(Experimental)
Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
carboplatin
Carboplatin will be administered as per schedule specified in the respective arm.
mehd7945a Duligotuzumab
MEHD7945A will be administered as per schedule specified in the respective arms.
paclitaxel
Paclitaxel will be administered as per schedule specified in the respective arm.

Primary Outcomes

Measure
Percentage of Participants With DLTs
time frame: Cycle 1 Day 1 through Cycle 1 Day 21 (Cycle length = 3 weeks)
Percentage of Participants with Adverse Events
time frame: From Baseline until 45 days after last dose of study drug or until initiation of another anti-cancer therapy, withdrawal or lost to follow-up, whichever occurs first (up to approximately 3 years)

Secondary Outcomes

Measure
Area Under Concentration-Time Curve From Day 1 to 21 (AUC0-21d) of MEHD7945A
time frame: Pre-infusion (0 hour), 30 minutes post-infusion (infusion duration=90 minutes) on Day 1 of Cycles 1, 2, 3, 4, 8; 4 hours post-infusion on Day 1 of Cycle 1; Days 2, 4, 8, 15 of Cycle 1 (each cycle = 3 weeks)
Maximum Serum Concentration (Cmax) of MEHD7945A
time frame: 30 minutes and 4 hours post-infusion (infusion duration=90 minutes) on Day 1 of Cycle 1; 30 min post-infusion on Day 1 of Cycles 2, 3, 4, and 8 (each cycle = 3 weeks)
Minimum Serum Concentration (Cmin) of MEHD7945A
time frame: Pre-infusion (0 hour) on Day 1 of Cycles 1, 2, 3, 4, and 8 (each cycle = 3 weeks)
Cmax of Cisplatin
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 2, 4, 6 hours post-infusion (infusion duration = 1-2 hours) on Day 1 of Cycle 1 (Cycle length = 3 weeks)
Area Under Concentration-Time Curve From 0 to 6 Hours (AUC0-6h) of Cisplatin
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 2, 4, 6 hours post-infusion (infusion duration = 1-2 hours) on Day 1 of Cycle 1 (Cycle length = 3 weeks)
Plasma Concentrations of 5-FU
time frame: Pre-infusion (0 hour) on Day 1 of Cycle 1; Day 2 of Cycle 1 (Cycle length = 3 weeks)
Cmax of Carboplatin
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 2, 4, 6 hours post-infusion (infusion duration = 15-30 minutes) on Day 1 of Cycle 1 (Cycle length = 3 weeks)
AUC0-6h of Carboplatin
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 2, 4, 6 hours post-infusion (infusion duration = 15-30 minutes) on Day 1 of Cycle 1 (Cycle length = 3 weeks)
Cmax Normalized by Dose (Cmax/D) of Carboplatin
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 2, 4, 6 hours post-infusion (infusion duration = 15-30 minutes) on Day 1 of Cycle 1 (Cycle length = 3 weeks)
AUC0-6h Normalized by Dose (AUC0-6h/D) of Carboplatin
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 2, 4, 6 hours post-infusion (infusion duration = 15-30 minutes) on Day 1 of Cycle 1 (Cycle length = 3 weeks)
Cmax of Paclitaxel
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 3, 5 hours post-infusion (infusion duration = 3 hours) on Day 1 of Cycle 1, Day 2 of Cycle 1 (Cycle length = 3 weeks)
Area Under Concentration-Time Curve From 0 to 24 Hours (AUC0-24h) of Paclitaxel
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 3, 5 hours post-infusion (infusion duration = 3 hours) on Day 1 of Cycle 1, Day 2 of Cycle 1 (Cycle length = 3 weeks)
Plasma Half-Life (t1/2) of Paclitaxel
time frame: Pre-infusion (0 hour), 0 to 5 minutes and 1, 3, 5 hours post-infusion (infusion duration = 3 hours) on Day 1 of Cycle 1, Day 2 of Cycle 1 (Cycle length = 3 weeks)
Percentage of Participants With Anti-Therapeutic Antibodies to MEHD7945A
time frame: Pre-dose (0 hour) on Day 1 of Cycles 1, 4, 8 (each cycle = 3 weeks) and at study completion (approximately 3 years)
Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
time frame: From first dose of study drug until disease progression or death (up to approximately 3 years)
Percentage of Participants With Disease Control (CR or PR or Stable Disease [SD]) as Assessed by Modified RECIST v1.1 Criteria
time frame: From first dose of study drug until disease progression or death (up to approximately 3 years)
Duration of Objective Response (CR or PR) as Assessed by Modified RECIST v1.1 Criteria
time frame: From first occurrence of CR or PR until relapse or death (up to approximately 3 years)
Progression-Free Survival as Assessed by Modified RECIST v1.1 Criteria
time frame: From first dose of study drug until disease progression or death (up to approximately 3 years)

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria

  • Histologically confirmed R/M SCCHN of mucosal origin (e.g., oral cavity, oropharynx, hypopharynx, larynx) that is not amenable to further curative local therapy (e.g., surgery, radiation including re-irradiation) (1L R/M)
  • Participants with unknown primary SCCHN presumed to be of head and neck mucosal origin are eligible if they meet all other entry criteria
  • For participants who present with de novo metastatic disease, no prior systemic chemotherapy is allowed
  • For participants with recurrent SCCHN, prior systemic therapy is allowed if it was given as part of induction or definitive therapy. If participants have received prior combined chemo-radiation therapy, they must be off therapy for at least 3 months
  • Consent to provide archival tumor tissue for biomarker testing
  • Life expectancy greater than or equal to (>/=) 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Disease that is measurable per modified RECIST v1.1
  • Adequate bone marrow and organ function

Exclusion Criteria

  • Nasopharyngeal cancer
  • Prior treatment with an investigational or approved agent for the purpose of inhibiting human epidermal growth factor receptor (HER) family members. This includes, but is not limited to, cetuximab, panitumumab, erlotinib, gefitinib, and lapatinib
  • Prior treatment with an epidermal growth factor receptor (EGFR) inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed/terminated >/= 3 months before study enrollment
  • Major surgical procedure within 4 weeks prior to Day 1
  • Leptomeningeal disease as the only manifestation of the current malignancy
  • Active infection requiring antibiotics
  • Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
  • Current severe, uncontrolled systemic disease
  • History of cardiac heart failure of New York Heart Association Class II or greater or serious cardiac arrhythmia requiring treatment (except for atrial fibrillation and paroxysmal supraventricular tachycardia)
  • History of myocardial infarction within 6 months prior to Cycle 1, Day 1, or history of unstable angina
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • History of bleeding diathesis or coagulopathy other than that due to anticoagulation therapy
  • Clinically significant gastrointestinal (GI) bleeding within 6 months prior to Cycle 1, Day 1
  • History of interstitial lung disease (ILD)
  • History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of therapy
  • Known human immunodeficiency virus (HIV) infection
  • Untreated/active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
  • Pregnant or lactating women
  • Malignancies other than SCCHN within 5 years prior to enrollment, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix or skin (e.g., melanoma in situ) or indolent prostate cancer

Additional Information

Official title A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Genentech, Inc..